Asunto(s)
Transfusión de Eritrocitos/efectos adversos , Eritrocitos/inmunología , Sueros Inmunes/inmunología , Glicoproteínas de Membrana/inmunología , Metaloendopeptidasas/inmunología , Anemia Hemolítica/inmunología , Anemia Hemolítica/prevención & control , Animales , Modelos Animales de Enfermedad , Humanos , Sueros Inmunes/administración & dosificación , Isoanticuerpos/inmunología , RatonesRESUMEN
BACKGROUND: Red blood cell (RBC) alloantibodies to nonself antigens may develop after transfusion or pregnancy, leading to morbidity and mortality in the form of hemolytic transfusion reactions or hemolytic disease of the newborn. A better understanding of the mechanisms of RBC alloantibody induction, or strategies to mitigate the consequences of such antibodies, may ultimately improve transfusion safety. However, such studies are inherently difficult in humans. STUDY DESIGN AND METHODS: We recently generated transgenic mice with RBC-specific expression of the human KEL glycoprotein, specifically the KEL2 or KEL1 antigens. Herein, we investigate recipient alloimmune responses to transfused RBCs in this system. RESULTS: Transfusion of RBCs from KEL2 donors into wild-type recipients (lacking the human KEL protein but expressing the murine KEL ortholog) resulted in dose-dependent anti-KEL glycoprotein immunoglobulin (Ig)M and IgG antibody responses, enhanced by recipient inflammation with poly(I:C). Boostable responses were evident upon repeat transfusion, with morbid-appearing alloimmunized recipients experiencing rapid clearance of transfused KEL2 but not control RBCs. Although KEL1 RBCs were also immunogenic after transfusion into wild-type recipients, transfusion of KEL1 RBCs into KEL2 recipients or vice versa failed to lead to detectable anti-KEL1 or anti-KEL2 responses. CONCLUSIONS: This murine model, with reproducible and clinically significant KEL glycoprotein alloantibody responses, provides a platform for future mechanistic studies of RBC alloantibody induction and consequences. Long-term translational goals of these studies include improving transfusion safety for at-risk patients.
Asunto(s)
Transfusión de Eritrocitos/métodos , Eritrocitos/inmunología , Isoanticuerpos/biosíntesis , Sistema del Grupo Sanguíneo de Kell/inmunología , Anemia Hemolítica/genética , Anemia Hemolítica/inmunología , Animales , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/genética , Incompatibilidad de Grupos Sanguíneos/genética , Incompatibilidad de Grupos Sanguíneos/inmunología , Eritrocitos/metabolismo , Humanos , Inflamación/inmunología , Sistema del Grupo Sanguíneo de Kell/genética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Poli I-CRESUMEN
Autoantibodies and alloantibodies can damage self-tissue or transplanted tissues through either fixation of complement or ligation of FcγRs. Several pathways have been described that imbue self-tissues with resistance to damage from complement fixation, as a protective measure against damage from these Abs. However, it has been unclear whether parallel pathways exist to provide protection from FcγR ligation by bound Abs. In this article, we describe a novel pathway by which cell surface Ag is specifically decreased as a result of Ab binding (Ag modulation) to the extent of conferring protection to recognized cells from Fcγ-dependent clearance. Moreover, the Ag modulation in this system requires FcγR ligation. Together, these findings provide unique evidence of self-protective pathways for FcγR-mediated Ab damage.
Asunto(s)
Modulación Antigénica/inmunología , Eritrocitos/inmunología , Receptores de IgG/inmunología , Animales , Antígenos de Superficie/inmunología , Autoanticuerpos/inmunología , Proteínas del Sistema Complemento/inmunología , Inmunoglobulina G/inmunología , Isoanticuerpos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de IgG/metabolismoRESUMEN
Hemolytic transfusion reactions (HTRs) due to incompatible red blood cell (RBC) transfusions are a leading cause of transfusion associated death. Although many transfused incompatible RBCs are cleared, some remain in circulation despite the presence of RBC-specific antibodies, potentially due to "antigen modulation." With a goal of better understanding incompatible RBC clearance, we generated a murine model with RBC-specific expression of a clinically significant human antigen (KEL2) known to be involved in antigen modulation as well as in HTRs. Wild-type (WT) recipients transfused with transgenic KEL2 RBCs generated anti-KEL glycoprotein alloantibodies, which fixed complement, led to intravascular hemolysis, and resulted in decreased levels of KEL2 antigen detectable on cells remaining in circulation. Antigen modulation did not appear to solely reflect removal of RBCs with higher antigen expression, because cells continued to display antigen modulation in the absence of significant clearance. Recipients genetically lacking complement exhibited lesser degrees of incompatible RBC clearance and antigen modulation in comparison with WT or FcγR knock-out (KO) animals, suggesting a role for complement in RBC clearance. In summary, this HTR model may serve as a platform to test strategies to downmodulate antigen and inhibit incompatible RBC clearance, thus potentially mitigating transfusion dangers.
Asunto(s)
Anticuerpos/inmunología , Antígenos/inmunología , Complemento C3/metabolismo , Eritrocitos/inmunología , Animales , Incompatibilidad de Grupos Sanguíneos/inmunología , Incompatibilidad de Grupos Sanguíneos/patología , Supervivencia Celular , Transfusión de Eritrocitos , Eritrocitos/patología , Glicoproteínas/inmunología , Humanos , Inmunización Pasiva , Isoanticuerpos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Unión Proteica , Receptores de IgG/metabolismo , Factores de TiempoRESUMEN
Exposure to nonself red blood cell (RBC) antigens, either from transfusion or pregnancy, may result in alloimmunization and incompatible RBC clearance. First described as a pregnancy complication 80 years ago, hemolytic disease of the fetus and newborn (HDFN) is caused by alloimmunization to paternally derived RBC antigens. Despite the morbidity/mortality of HDFN, women at risk for RBC alloimmunization have few therapeutic options. Given that alloantibodies to antigens in the KEL family are among the most clinically significant, we developed a murine model with RBC-specific expression of the human KEL antigen to evaluate the impact of maternal/fetal KEL incompatibility. After exposure to fetal KEL RBCs during successive pregnancies with KEL-positive males, 21 of 21 wild-type female mice developed anti-KEL alloantibodies; intrauterine fetal anemia and/or demise occurred in a subset of KEL-positive pups born to wild type, but not agammaglobulinemic mothers. Similar to previous observations in humans, pregnancy-associated alloantibodies were detrimental in a transfusion setting, and transfusion-associated alloantibodies were detrimental in a pregnancy setting. This is the first pregnancy-associated HDFN model described to date, which will serve as a platform to develop targeted therapies to prevent and/or mitigate the dangers of RBC alloantibodies to fetuses and newborns.
Asunto(s)
Anemia Hemolítica/inmunología , Eritrocitos/citología , Isoanticuerpos/inmunología , Sistema del Grupo Sanguíneo de Kell/inmunología , Modelos Animales , Anemia Hemolítica/genética , Animales , Transfusión Sanguínea , Citocinas/metabolismo , Femenino , Proteínas Fluorescentes Verdes/metabolismo , Inmunoglobulina G/inmunología , Sistema del Grupo Sanguíneo de Kell/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Embarazo , PreñezRESUMEN
Hemolytic transfusion reactions represent one of the most common causes of transfusion-related mortality. Although many factors influence hemolytic transfusion reactions, complement activation represents one of the most common features associated with fatality. In this paper we will focus on the role of complement in initiating and regulating hemolytic transfusion reactions and will discuss potential strategies aimed at mitigating or favorably modulating complement during incompatible red blood cell transfusions.